

**ABSTRACT**

The present invention relates to the use of compounds from the group of 1-oxadibenzo[*e,h*]azulenes and of their pharmacologically acceptable salts and solvates in a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other neurotransmitters.